Vittamed company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Dead

Total Raised


Last Raised


About Vittamed

Vittamed is a neurodiagnostics medical device company with offices in Kaunas, Lithuania and Boston, USA. The company has developed a suite of ultrasound-based devices to non-invasively measure the absolute value of intracranial pressure (ICP), real-time cerebral blood flow autoregulation (CA), and intracranial volumetric wave monitoring. The non-invasive diagnostic methods have been clinically tested and proven in leading neuro centers in Europe and the United States.

Vittamed Headquarter Location

1776 Massachusetts Avenue

Lexington, Massachusetts, 02420,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vittamed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vittamed is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,454 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Latest Vittamed News

Proficiency, flexibility help match patients with appropriate MIGS device

Feb 7, 2022

Berdahl J. MIGS devices. Presented at: Hawaiian Eye 2022; Jan. 15-21, 2022; Waikoloa, Hawaii. Disclosures: Berdahl reports having financial disclosures for Alcon, Allergan, Avedro, Aurea Medical, Bausch + Lomb, CorneaGen, Dakota Lions Eye Bank, Equinox, Expert Opinion, Glaukos, Gore, Imprimis/Harrow Health, Johnson & Johnson, Kala, Kedalion, Melt Pharmaceuticals, MicroOptix, New World Medical, Ocular Surgical Data, Ocular Therapeutix, Omega Ophthalmics, Orasis, Oyster Point, RxSight, Surface Inc., Tarsus, TearClear, Vittamed, Vance Thompson Vision, Verana Health (DigiSight), Visionary Ventures and Zeiss. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio WAIKOLOA, Hawaii — With several good MIGS options, the choice often comes down to matching the procedure with the patient, according to a presentation at Hawaiian Eye 2022. John Berdahl, MD, said devices such as the Hydrus microstent (Ivantis/Alcon) and the iStent (Glaukos) have shown efficacy in reducing IOP and medications in patients with glaucoma. “So, how do you choose?” Berdahl said. “I always ask myself the question, ‘What would I want if it was my eye?’” One thing that helps, Berdahl said, is the quality of data provided by recent studies such as HORIZON, which includes outcomes of up to 5 years. In the study, researchers randomly assigned 556 eyes to receive the Hydrus microstent or no additional treatment after phacoemulsification. After 5 years, 66% of patients who received the microstent required no medications compared with 46% of patients who underwent cataract surgery alone. Patients in the microstent group also had a greater reduction in medication-free IOP. When starting MIGS procedures, Berdahl said surgeons need to consider a few factors. First is determining which patients are candidates. “It’s currently indicated for mild to moderate glaucoma,” he said. “We’re not restricted by what we’re able to do by the label, but we are restricted on what we may get paid for.” Second is being proficient but flexible when it comes to choosing a device. “There isn’t an algorithm,” Berdahl said. “My advice to you, if you’re getting into the MIGS space, is to choose the one that resonates with you and get really good at it. Once you have visualization down, broaden out into other procedures, so you can do your best job at matching the procedure to the patient, not trying to force the patient into the procedure that you’re good at.” In a disease that includes both medical and surgical treatments, Berdahl said MIGS plays an important role in glaucoma. “We want to balance efficacy and safety,” he said. “MIGS has filled a huge gap.” Read more about

  • Where is Vittamed's headquarters?

    Vittamed's headquarters is located at 1776 Massachusetts Avenue, Lexington.

  • What is Vittamed's latest funding round?

    Vittamed's latest funding round is Series A.

  • How much did Vittamed raise?

    Vittamed raised a total of $10M.

  • Who are the investors of Vittamed?

    Investors of Vittamed include Imprimatur Capital and Xeraya Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.